Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lecicarbon is a physical-acting laxative suppository developed by Athenstaedt, primarily indicated for the treatment of various forms of constipation and for bowel evacuation prior to diagnostic procedures (such as rectoscopy or sigmoidoscopy) or surgery. The formulation consists of sodium bicarbonate and sodium dihydrogen phosphate embedded in a water-soluble fat base. Upon rectal administration, these components react in the presence of moisture to release carbon dioxide gas. The resulting gas bubbles provide a mechanical stimulus to the rectal mucosa and distend the rectal wall, effectively mimicking the natural filling of the rectum and triggering the natural defecation reflex (peristalsis). This mechanism typically induces bowel evacuation within 15 to 30 minutes. Because its action is purely physical and localized, Lecicarbon avoids the systemic absorption and potential electrolyte imbalances associated with many chemical laxatives, making it suitable for a wide range of patients, including children and pregnant women.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lecicarbon.